What makes you think they won’t get approval?
Their data is obviously good and compelling.
I do agree on the business front, they’re a dumpster fire, but the FDA is looking at efficacy, benefit versus risk, and in those categories they score very high IMO.
I agree that this is a short term trade for now pending some resolution of their cash situation and competent management, but I do think they get approval.
Murocman